ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

formoterol

Also written as “Formoterol Fumarate”, “budesonide/formoterol” and “Formoterol”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic · Asthma, Exercise-Induced, led by 18 companies.

Drug pageFormoterol: every studyMany companies study it; this page follows only the 137 they lead. All 190 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 4, 2006137 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only632 open or runningphase 4since Jan 4, 2006Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Chiesi Farmaceuticiits history only200 open or runningphase 4since Nov 29, 2010Oct 30, 2006none ahead
Viatrisits history only160 open or runningphase 4since Nov 29, 2011Sep 13, 2005none ahead
Novartisits history only60 open or runningphase 4since Jul 26, 2005Jul 26, 2005none ahead
Sumitomo Pharma60 open or runningphase 4since Jan 17, 2007Jul 8, 2003none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Mundipharmaits history only30 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Mar 9, 2011Mar 9, 2011none ahead
Boehringer Ingelheimits history only20 open or runningphase 2since Sep 11, 2014Sep 11, 2014none ahead

Also a collaborator on its studies: Parexel, CISCRP, eResearchTechnology, Menarini Group, Integrated Therapeutics Group and Pacira BioSciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sumitomo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2003First studies: 2 phase 3 studies in Pulmonary Disease, Chronic ObstructiveFirst studyNCT00064415, NCT00064402
  2. Jan 17, 2007Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT00424528 · 235 enrolled · United States
  3. Dec 21, 2007Phase 2 study in AsthmaNCT00583947 · 53 enrolled · United States
  4. May 23, 2008Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT00685529 · 24 enrolled · United States
  5. May 26, 2009Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT00909779 · 841 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Sumitomo Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00909779Pulmonary Disease, Chronic Obstructive · United States3CompletedJun 2012841
NCT00685529Pulmonary Disease, Chronic Obstructive · United States2CompletedOct 200524
NCT00583947Asthma · United States2CompletedDec 200853
NCT00424528Pulmonary Disease, Chronic Obstructive · United States4CompletedOct 2007235
NCT00064415Pulmonary Disease, Chronic Obstructive · United States3CompletedDec 2004799
NCT00064402Pulmonary Disease, Chronic Obstructive · United States3CompletedMar 2004741

How it is read

Names in the registry

  • “Formoterol Fumarate”, 14 entries
  • “budesonide/formoterol”, 10 entries
  • “Formoterol”, 9 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.